Literature DB >> 27252512

Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia.

Raajit Rampal1, Maria E Figueroa2.   

Abstract

Wilms tumor 1 (WT1) has long been implicated in acute myeloid leukemia. It has been described to be both overexpressed and mutated in different forms of acute myeloid leukemia, and overexpression has been reported to play a prognostic role in this disease. However, the precise mechanism through which WT1 may play a role in leukemogenesis has remained elusive. In recent years, new evidence has emerged that points towards a novel role of WT1 mutations in the deregulation of epigenetic programs in leukemic cells through its interaction with TET proteins. Herein we review the current status of the field and its therapeutic and prognostic implications in acute myeloid leukemia. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Year:  2016        PMID: 27252512      PMCID: PMC5013955          DOI: 10.3324/haematol.2015.141796

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  74 in total

1.  Role of the WT1 tumor suppressor in murine hematopoiesis.

Authors:  Julia A Alberta; Gregory M Springett; Helen Rayburn; Thomas A Natoli; Janet Loring; Jordan A Kreidberg; David Housman
Journal:  Blood       Date:  2002-12-05       Impact factor: 22.113

2.  Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis.

Authors:  P N Baird; P J Simmons
Journal:  Exp Hematol       Date:  1997-04       Impact factor: 3.084

3.  Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway.

Authors:  K Ito; Y Oji; N Tatsumi; S Shimizu; Y Kanai; T Nakazawa; M Asada; T Jomgeow; S Aoyagi; Y Nakano; H Tamaki; N Sakaguchi; T Shirakata; S Nishida; M Kawakami; A Tsuboi; Y Oka; Y Tsujimoto; H Sugiyama
Journal:  Oncogene       Date:  2006-03-06       Impact factor: 9.867

4.  Wt1 is not essential for hematopoiesis in the mouse.

Authors:  Linda King-Underwood; Suzanne Little; Mandy Baker; Robyn Clutterbuck; Sylvie Delassus; Tariq Enver; Clive Lebozer; Toon Min; Adrian Moore; Andreas Schedl; Kathy Pritchard-Jones
Journal:  Leuk Res       Date:  2005-02-17       Impact factor: 3.156

Review 5.  A clinical overview of WT1 gene mutations.

Authors:  M Little; C Wells
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

Review 6.  Assessment of minimal residual disease in acute myeloid leukemia.

Authors:  David Grimwade; Paresh Vyas; Sylvie Freeman
Journal:  Curr Opin Oncol       Date:  2010-11       Impact factor: 3.645

7.  Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.

Authors:  Aline Renneville; Nicolas Boissel; Virginie Zurawski; Laura Llopis; Valéria Biggio; Olivier Nibourel; Nathalie Philippe; Xavier Thomas; Hervé Dombret; Claude Preudhomme
Journal:  Cancer       Date:  2009-08-15       Impact factor: 6.860

8.  Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.

Authors:  Verena Ingeborg Gaidzik; Richard Friedrich Schlenk; Simone Moschny; Annegret Becker; Lars Bullinger; Andrea Corbacioglu; Jürgen Krauter; Brigitte Schlegelberger; Arnold Ganser; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2009-02-12       Impact factor: 22.113

9.  Expression of the Wilms' tumor gene (WT1) in human leukemias.

Authors:  H Miwa; M Beran; G F Saunders
Journal:  Leukemia       Date:  1992-05       Impact factor: 11.528

10.  Mutations in the Wilms' tumor gene WT1 in leukemias.

Authors:  L King-Underwood; J Renshaw; K Pritchard-Jones
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

View more
  30 in total

Review 1.  Ca2+ as a therapeutic target in cancer.

Authors:  Scott Gross; Pranava Mallu; Hinal Joshi; Bryant Schultz; Christina Go; Jonathan Soboloff
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

2.  Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis.

Authors:  Elodie Pronier; Robert L Bowman; Jihae Ahn; Jacob Glass; Cyriac Kandoth; Tiffany R Merlinsky; Justin T Whitfield; Benjamin H Durham; Antoine Gruet; Amritha Varshini Hanasoge Somasundara; Raajit Rampal; Ari Melnick; Richard P Koche; Barry S Taylor; Ross L Levine
Journal:  Blood       Date:  2018-07-31       Impact factor: 22.113

3.  Wilms' tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease.

Authors:  Vishwaraj Sontake; Rajesh K Kasam; Debora Sinner; Thomas R Korfhagen; Geereddy B Reddy; Eric S White; Anil G Jegga; Satish K Madala
Journal:  JCI Insight       Date:  2018-08-23

4.  Implications of the Wilms' Tumor Suppressor Wt1 in Cardiomyocyte Differentiation.

Authors:  Nicole Wagner; Marina Ninkov; Ana Vukolic; Günseli Cubukcuoglu Deniz; Minoo Rassoulzadegan; Jean-François Michiels; Kay-Dietrich Wagner
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

5.  Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.

Authors:  Christian Augsberger; Gerulf Hänel; Wei Xu; Vesna Pulko; Lydia Jasmin Hanisch; Angelique Augustin; John Challier; Katharina Hunt; Binje Vick; Pier Eduardo Rovatti; Christina Krupka; Maurine Rothe; Anne Schönle; Johannes Sam; Emmanuelle Lezan; Axel Ducret; Daniela Ortiz-Franyuti; Antje-Christine Walz; Jörg Benz; Alexander Bujotzek; Felix S Lichtenegger; Christian Gassner; Alejandro Carpy; Victor Lyamichev; Jigar Patel; Nikola Konstandin; Antje Tunger; Marc Schmitz; Michael von Bergwelt-Baildon; Karsten Spiekermann; Luca Vago; Irmela Jeremias; Estelle Marrer-Berger; Pablo Umaña; Christian Klein; Marion Subklewe
Journal:  Blood       Date:  2021-12-23       Impact factor: 25.476

Review 6.  Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.

Authors:  Habsah Aziz; Chow Y Ping; Hamidah Alias; Nurul-Syakima Ab Mutalib; Rahman Jamal
Journal:  Front Pharmacol       Date:  2017-12-07       Impact factor: 5.810

7.  Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways.

Authors:  Y Lyu; J Lou; Y Yang; J Feng; Y Hao; S Huang; L Yin; J Xu; D Huang; B Ma; D Zou; Y Wang; Y Zhang; B Zhang; P Chen; K Yu; E W-F Lam; X Wang; Q Liu; J Yan; B Jin
Journal:  Leukemia       Date:  2017-04-12       Impact factor: 11.528

8.  MicroRNA-181 as a prognostic biomarker for survival in acute myeloid leukemia: a meta-analysis.

Authors:  Qiang Guo; Junwen Luan; Ni Li; Zhen Zhang; Xiaoxiao Zhu; Lin Zhao; Ran Wei; Linlin Sun; Yin Shi; Xunqiang Yin; Na Ding; Guosheng Jiang; Xia Li
Journal:  Oncotarget       Date:  2017-07-12

9.  Chromosome t(7;11)(p15;p15) translocation in acute myeloid leukemia coexisting with multilineage dyspoiesis and mutations in NRAS and WT1: A case report and literature review.

Authors:  Jingke Yang; Xiaodong Lyu; Xinghu Zhu; Xiangguang Meng; Wenli Zuo; Hao Ai; Mei Deng
Journal:  Oncol Lett       Date:  2017-03-07       Impact factor: 2.967

Review 10.  Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease.

Authors:  Serena Tommasini-Ghelfi; Kevin Murnan; Fotini M Kouri; Akanksha S Mahajan; Jasmine L May; Alexander H Stegh
Journal:  Sci Adv       Date:  2019-05-22       Impact factor: 14.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.